Despite HE4 being elevated in about 80% of ovarian cancer cases, multiple studies, including meta-analyses, have highlighted its role as a potential complement to CA 125, particularly in distinguishing benign endometriotic and inflammatory lesions in younger women [14,41]. Here, WFDC2 is linked to ovarian carcinoma.